Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and the Beyond Batten Disease Foundation (BBDF) today announced the European Commission’s decision to award “orphan medicinal product” designation to the two active ingredients, trehalose and miglustat, used in the drug candidate BBDF-101 for Batten disease, a rare, fatal genetic disorder affecting the metabolism of the central nervous system for which there is currently no treatment.
